A best evidence topic was written according to a structured protocol. The question addressed was 'whether a sleeve lobectomy results in a better survival rate than a pneumonectomy in suitable patients?' Altogether, more than 327 papers were found using the reported search, of which 15 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude in the biggest meta-analysis of nearly 3000 patients, the five-year survival was 50% for sleeve lobectomy compared to 30% for pneumonectomy. Operative mortality was 3% vs. 6% for pneumonectomy, and locoregional recurrence was 17% vs. 30%. These results are broadly consistent across all the 13 cohort studies presented here many of which document a 20-year single centre experience or more. There are significant issues in all cohort studies on this subject as, due to their non-randomized nature, the reason for not performing a sleeve resection may well have been more advanced disease, which would necessarily mean that the pneumonectomy patients would have a lower expected survival and higher local recurrence. In addition, there have been many large cohort studies to date and thus no more are required, as future studies are unlikely to resolve this issue. Thus, the only study that would adequately correct for this issue would be a randomized trial, but to prove a 10% increase in five-year survival a 300 patient study would be needed. This is bigger than any study ever done in this area and as some centres took 30 years to collect these numbers of potential sleeve patients an RCT is not a realistic possibility. Therefore, we conclude that no more cohort studies should be performed, as the results will be consistent with the meta-analyses and an RCT to eliminate their bias is unattainable, and thus no more research should be done on this topic and surgeons should use the figures presented above and in more detail in this best evidence topic to govern their management in the future. ᮊ
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In wpatients undergoing lung resection for non-small cell lung cancerx is wsleeve lobectomyx superior to wpneumonectomyx in terms of wsurvival.x
Clinical scenario
In theatre, you are operating on a 57-year-old with the intention of a lobectomy due to a non-small cell carcinoma (NSCLC) in the upper lobe of the right lung. You find that the tumour, however, extends into the right main bronchus. Facing two options, your assistant suggests performing a pneumonectomy as the sleeve lobectomy is quite technically difficult and you could cause a bronchopleural fistula. However, you feel that the patient would benefit from a *Corresponding authors: Tel.yfax: q44-77-49152951. E-mail address: joseph.stallard@ncl.ac.uk (J. Stallard).
sleeve lobectomy in terms of lung function and survival but you are not sure of the data for this and thus resolve to check the literature after the operation.
Search strategy
Medline 1950 to May 2007 using OVID interface wSleeve Lobectomy.mp OR Sleeve resection.mpx and wexp Pneumonectomy OR Pneumonectomy.mpx
Search outcome
Three hundred and twenty-seven papers were found using the reported search. From these, 15 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
Results
Ma et al. w2x performed a meta-analysis of 12 studies in 2007, they showed that a sleeve lobectomy can be carried out instead of pneumonectomy without increasing morbidity and mortality. They in fact found that sleeve lobectomy follow-up will be needed for a definitive answer SL, sleeve lobectomy; PN, pneumonectomy; NSCLC, non-small cell lung cancer; CI, confidence interval.
has a better long-term survival, their results for survival were generated from 10 papers with nearly 3000 patients. At one year, a risk difference of 0.10 w95% confidence interval (CI): 0.07-0.18x was reported in favour of the sleeve lobectomy group. They reported a five-year survival of 50.3% in the sleeve lobectomy group compared to 30.6% in the pneumonectomy group. Ferguson and Lehman w3x also carried out a meta-analysis on 12 studies. They showed that sleeve lobectomy is associated with better long-term survival and quality of life than pneumonectomy in patients with early stage lung cancer. This was particularly evident from the quality adjusted life years quoted which were 4.37 for sleeve lobectomy and 2.48 for the pneumonectomy group.
Melloul et al. w4x carried out a retrospective study which suggested sleeve lobectomy has a therapeutic advantage over pneumonectomy. This was due to sleeve lobectomies resulting in a higher postoperative FEV than pneumonec-1 tomies. They also highlighted that sleeve lobectomy gave more favourable outcomes in overall complication rate and 30-day mortality.
A prospective study carried out by Martin-Ucar et al. w6x reported similar, favourable results for sleeve lobectomy with regards to preservation of FEV wFEV loss sleeve J. Stallard et al. / Interactive CardioVascular and Thoracic Surgery 11 (2010) [660] [661] [662] [663] [664] [665] [666] Best Evidence Topic lobectomy 170 ml (ranges0-500 ml), pneumonectomy 620 ml (ranges200-1400 ml) P-0.0003x and 30-day mortality. Okada et al. w5x and Ludwig et al. w8x , concluded that sleeve lobectomy should be carried out over pneumonectomy whenever technically possible. Both of their studies demonstrated that sleeve lobectomy has a better survival rate and a lower complication rate. Kim et al. w7x also had similar results, but restricted their recommendation for sleeve lobectomy to patients with negative lymph nodes as they found a higher local recurrence rate in the sleeve lobectomy group. Takeda et al. w9x, Gaissert et al. w10x and Ghiribelli et al. w13x found sleeve lobectomy and pneumonectomy to have similar outcomes for survival and complication rate. They all, however, recommend sleeve lobectomy to be the first choice procedure wherever possible as there is preservation of lung parenchyma and therefore a better lung function and quality of life. Suen et al. w12x found similar outcomes between the two procedures when the NSCLC affected the main bronchus, although with low-grade tumours, they found sleeve lobectomy patients to have far superior shortand long-term outcomes.
Yoshino et al. w11x found sleeve lobectomy to be safer than pneumonectomy with lower postoperative complications wsleeve lobectomy -13.7%, pneumonectomy -24.1% (P-0.05)x and operative-related mortality wsleeve lobectomy -0%, pneumonectomy -6.9% (P-0.05)x. They found no statistical difference in recurrence rate between the two procedures. Deslauriers et al. w14x and Bagan et al. w15x found sleeve lobectomy to be the safer option for patients suffering from resectable NSCLC as it gives better survival (Ps0.021 and Ps0.0025, respectively) and lower mortality rates. They also discovered sleeve lobectomy to have a lower locoregional recurrence than pneumonectomy.
Lausberg et al. w16x found sleeve lobectomy to be a better option than pneumonectomy as the bronchial complications were 0% and 7.5%, respectively (P-0.001). All other outcomes were found to be similar, however, they identified that to give a definitive answer on local recurrence they needed a longer follow-up.
Clinical bottom line
Results from two meta-analyses and the 13 largest cohort studies on this subject, presented in this paper conclusively show improved survival, reduced loss in lung function, improved operative mortality and in most cases no difference in locoregional recurrence. In the biggest metaanalysis of nearly 3000 patients, the five-year survival was 50% for sleeve lobectomy compared to 30% for pneumonectomy. Operative mortality was 3% vs. 6% for pneumonectomy, and locoregional recurrence 17% vs. 30%. These results are broadly consistent across all the cohort studies.
There are significant issues in all cohort studies on this subject, as due to their non-randomized nature, the reason for not performing a sleeve resection may well have been more advanced disease in many of these cases, which would necessarily mean that the pneumonectomy patients would have a lower expected survival and higher local recurrence. In addition, there have been many large cohort studies to date and thus no more are required as this issue could not be overcome in the future. Thus, the only study that would adequately correct for this issue would be a randomized trial, but to prove a 10% increase in five-year survival a 300 patient study is needed. This is bigger than any cohort study ever done in this area and some centres took up to 30 years to collect these numbers of potential sleeve patients, thus we conclude that an RCT is not a realistic possibility. Therefore, we conclude that no more cohort studies should be performed, as the results will be consistent with the meta-analyses and an RCT to eliminate their bias is unattainable, and thus no more research should be done on this topic and surgeons should use the figures presented above to govern their management in the future.
